Scleral collagen cross linkage in progressive myopia.

Publisher: Medknow Publications Country of Publication: India NLM ID: 0405376 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-3689 (Electronic) Linking ISSN: 03014738 NLM ISO Abbreviation: Indian J Ophthalmol Subsets: MEDLINE

Publication: Mumbai : Medknow Publications
Original Publication: Bombay : All-India Ophthalmological Society

Collagen*/chemistry ; Collagen*/metabolism ; Collagen*/therapeutic use ; Cross-Linking Reagents*/pharmacology ; Myopia, Degenerative*/pathology; Humans ; Cornea/drug effects ; Cornea/metabolism ; Cornea/pathology ; Sclera/drug effects ; Sclera/metabolism ; Sclera/pathology

High myopia is often associated with local ectasia and scleral thinning. The progression of myopia depends upon scleral biochemical and biomechanical properties. Scleral thinning is associated with decreased collagen fiber diameter, defective collagen fibrillogenesis, and collagen cross-linking. Reversing these abnormalities may make the sclera tougher and might serve as a treatment option for myopic progression. Collagen cross-linking is a natural process in the cornea and sclera, which makes the structure stiff. Exogenous collagen cross-linkage is artificially induced with the help of external mediators by using light and dark methods. In this systematic review, we discussed existing literature available on the internet on current evidence-based applications of scleral collagen cross-linking (SXL) by using different interventions. In addition, we compared them in tabular form in terms of their technique, mechanisms, cytotoxicity, and the stage of transition from preclinical to clinical development. Furthermore, we discussed the in-vivo technique to evaluate the post-SXL scleral biomechanical property and outcome in the human eye.
(Copyright © 2023 Copyright: © 2023 Indian Journal of Ophthalmology.)

Biomed Res Int. 2021 Jan 27;2021:8915867. (PMID: 33575355)
Int J Med Sci. 2021 Jan 1;18(1):109-119. (PMID: 33390779)
J Biomech Eng. 2015 Apr;137(4):041006. (PMID: 25531905)
Br J Ophthalmol. 2023 Jun;107(6):889-894. (PMID: 34670748)
Transl Vis Sci Technol. 2022 Oct 3;11(10):33. (PMID: 36269184)
Curr Eye Res. 2019 Feb;44(2):162-171. (PMID: 30222005)
Exp Eye Res. 2023 Feb;227:109387. (PMID: 36646298)
Front Med (Lausanne). 2021 Jul 02;8:655822. (PMID: 34277654)
Invest Ophthalmol Vis Sci. 2022 May 2;63(5):24. (PMID: 35594036)
Am J Ophthalmol. 2023 Aug;252:153-163. (PMID: 37030495)
Prog Retin Eye Res. 2020 Jan;74:100773. (PMID: 31412277)
Biomaterials. 2021 Apr;271:120735. (PMID: 33721571)
Biomed Opt Express. 2022 Sep 23;13(10):5434-5446. (PMID: 36425630)
PLoS One. 2019 May 13;14(5):e0216425. (PMID: 31083660)
Ophthalmology. 2023 Mar;130(3):286-296. (PMID: 36240954)
J Cataract Refract Surg. 2008 Apr;34(4):651-6. (PMID: 18361989)
J Control Release. 2022 Jul;347:314-329. (PMID: 35513208)
Curr Eye Res. 2020 Jun;45(6):718-725. (PMID: 31735063)
Pharmaceutics. 2021 Nov 26;13(12):. (PMID: 34959293)
Acta Ophthalmol Scand. 2005 Aug;83(4):477-82. (PMID: 16029274)
Asia Pac J Ophthalmol (Phila). 2021 Jan 22;10(2):161-166. (PMID: 33492849)
Biosci Rep. 2019 May 3;39(5):. (PMID: 30971499)
Transl Vis Sci Technol. 2021 Apr 29;10(5):1. (PMID: 34003978)
J Ophthalmol. 2015;2015:289467. (PMID: 25922758)
Ophthalmol Ther. 2023 Apr;12(2):853-866. (PMID: 36542255)
Biomed Opt Express. 2021 Sep 17;12(10):6341-6359. (PMID: 34745741)
BMC Ophthalmol. 2020 Dec 14;20(1):488. (PMID: 33317477)
Transl Vis Sci Technol. 2020 Aug 31;9(9):45. (PMID: 32934895)
Transl Vis Sci Technol. 2021 Apr 29;10(5):8. (PMID: 34328498)
Biochem Biophys Res Commun. 2020 Jul 12;528(1):134-139. (PMID: 32451081)

9007-34-5 (Collagen)
0 (Cross-Linking Reagents)

Date Created: 20231228 Date Completed: 20240129 Latest Revision: 20240505

20240505

PMC10941927

10.4103/IJO.IJO_1392_23

38153964